Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469366 | 0.75 | CA2 (0.33) | CA2KIF11GABRA1GABRB2ALDH1A1 | |
| SCHEMBL25527419 | 0.71 | CA2 (0.36) | CA2KIF11GABRA1GABRB2ALDH1A1 | |
| SCHEMBL22129270 | 0.71 | ALOX5 (0.34) | CA2KIF11 | |
| SCHEMBL24654883 | 0.67 | CA2 (0.32) | CA2 | |
| SCHEMBL22822780 | 0.67 | PARP1 (0.53) | — | |
| SCHEMBL15580435 | 0.66 | CA2 (0.46) | CA2KIF11GABRA1GABRB2ALDH1A1 | |
| SCHEMBL10558804 | 0.65 | ALOX5 (0.50) | ALDH1A1TDP1 | |
| SCHEMBL25696263 | 0.64 | CA2 (0.36) | CA2KIF11GABRA1GABRB2ALDH1A1 | |
| SCHEMBL811488 | 0.64 | DRD1 (0.46) | CA2KIF11GABRA1GABRB2ALDH1A1 | |
| SCHEMBL4968933 | 0.64 | BRD4 (0.37) | CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | CA2 3037/4885KIF11 1229/4885GABRA1 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.